Topical treatment with nanoliposomal Amphotericin B reduces early lesion growth but fails to induce cure in an experimental model of cutaneous leishmaniasis caused by Leishmania mexicana
- 1 September 2017
- journal article
- Published by Elsevier in Acta Tropica
- Vol. 173, 102-108
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Liposomal amphotericin B as a treatment for human leishmaniasisExpert Opinion on Emerging Drugs, 2012
- Efficacy of Topical Liposomal Amphotericin B versus Intralesional Meglumine Antimoniate (Glucantime) in the Treatment of Cutaneous LeishmaniasisJournal of Parasitology Research, 2011
- Liposomal amphotericin B treatment of cutaneous leishmaniasis due to Leishmania tropicaJournal of the European Academy of Dermatology and Venereology, 2010
- Drug resistance in leishmaniasisJournal of Global Infectious Diseases, 2010
- Complete Cure of Experimental Visceral Leishmaniasis with Amphotericin B in Stearylamine-Bearing Cationic Liposomes Involves Down-Regulation of IL-10 and Favorable T Cell ResponsesThe Journal of Immunology, 2008
- Chemotherapy of LeishmaniasisCurrent Pharmaceutical Design, 2002
- Activity of liposomal amphotericin B against experimental cutaneous leishmaniasisAntimicrobial Agents and Chemotherapy, 1997
- Amphotericin B Kills Unicellular Leishmanias by Forming Aqueous Pores Permeable to Small Cations and AnionsThe Journal of Membrane Biology, 1996
- Enhancement of macrophage superoxide anion production by amphotericin BAntimicrobial Agents and Chemotherapy, 1991
- Função renal em pacientes com leishmaniose muco-cutânea tratados com antimoniais pentavalentesRevista do Instituto de Medicina Tropical de São Paulo, 1985